Business Context and Reporting Period
This Form 6-K filing by Apollomics Inc. covers the month of December 2025, with a specific event date of December 11, 2025. The filing reports the termination of a material definitive agreement with Edison Oncology Holding Corporation regarding the development and commercialization of APL-122 (EO1001), an oral pan-ErbB inhibitor designed for ErbB-positive cancers with CNS metastases.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on the legal termination of a collaboration agreement rather than financial performance data.
Material Changes
- Termination of Agreement: Apollomics terminated the Development and License Agreement with Edison Oncology, originally dated January 31, 2021, and amended on August 11, 2023.
- Reason for Termination: The Company cited Edison's failure to fulfill material performance and reporting obligations.
- Disputed Obligations: Apollomics disputes any outstanding payment obligations claimed by Edison due to the alleged non-performance.
Outlook, Risks, and Management Commentary
Management states that the Company intends to vigorously defend its position and reserves all rights and remedies under the Agreement and applicable law. Regarding the financial impact, the Company explicitly states it does not expect this termination to have a material adverse effect on its overall financial condition or results of operations. The filing notes that the information is incorporated by reference into the Company's registration statements under the Securities Act.
Investor Verification Checklist
- Verify the specific performance and reporting obligations Edison allegedly failed to meet.
- Confirm the status of any outstanding payment claims and the Company's legal defense strategy.
- Assess the future development plans for APL-122 (EO1001) now that the collaboration has ended.
- Review subsequent filings for any updates on the dispute resolution or financial impact.